patients will receive 5ml of normal saline 0.9% topically 15 min before the expected end of surgery.

patients will receive 5ml of bupivacaine 0.5% topically 15 min before the expected end of surgery.

Thyroid Diseases

5ml of normal saline 0.9% topically 15 min will be installed topically around the ETT using ordinary syringe before the expected end of the surgery, this will be followed by manual ventilation using about the double tidal volume for 6-8 times or more to get air bubbles distributed within the upper airway to anesthetize the oropharynx and spread around ETT to the adjacent mucosal structures (laryngopharynx, larynx, and upper part of the trachea) then the cuff will be inflated to the previous pressure and the patient will be mechanically ventilated as usual.

normal saline 0.9%

5 ml of bupivacaine 0.5% will be installed topically around the ETT using ordinary syringe before the expected end of the surgery, this will be followed by manual ventilation using about the double tidal volume for 6-8 times or more to get air bubbles distributed within the upper airway to anesthetize the oropharynx and spread around ETT to the adjacent mucosal structures (laryngopharynx, larynx, and upper part of the trachea) then the cuff will be inflated to the previous pressure and patient will be mechanically ventilated as usual.

Bupivacaine Hydrochloride

Faculty of medicine, zagazig university

Topical Bupivacaine Effect On The Response To Awake Extubation During Emergence From General Anesthesia

Topical Bupivacaine Effect On The Response To Awake Extubation During Emergence From General Anesthesia In Patients Undergoing Elective Thyroidectomy. A Randomized Controlled Study

will be assessed as Grade 0: no cough; Grade 1: single cough with mild severity; Grade 2: cough lasting less than 5 s with moderate severity; Grade 3: sustained bouts of persistent cough more than 5 s.

removal of the endotracheal tube [ETT] while the patient is still in a deep plane of general anesthesia

will be assessed by visual analogue scale (VAS) scale, On a scale of 0-10, the patient will learn to quantify postoperative sore throat pain where 0= No pain and 10= Maximum worst pain.

planned after the completion of the study and publication

Shereen Elsayed Abd Ellatif

principal investigator, lecturer

Zagazig University

The patients will be divided randomly by a computer-generated randomization table into two equal groups

double-blinded ( patient and outcome assessors)

After randomization, 60 subjects will receive oral dexlansoprazole (Dexilant 60 mg, Takeda Co. Ltd, Tokyo, Japan) once daily before breakfast for 8 weeks. Subjects will record their symptoms (cough, globus, NCCP, heart burn, and acid regurgitation) at daytime and nighttime everyday for 8 weeks. Symptoms suspecting drug adverse effect including nausea, diarrhea, constipation, headache, dizziness, fatigue, flatulence, etc will be recorded for 8 weeks.

After randomization, 60 subjects will receive oral lansoprazole (Takepron OD 30 mg, Takeda Co. Ltd, Tokyo, Japan) once daily before breakfast for 8 weeks. Subjects will record their symptoms (cough, globus, NCCP, heart burn, and acid regurgitation) at daytime and nighttime everyday for 8 weeks. Symptoms suspecting drug adverse effect including nausea, diarrhea, constipation, headache, dizziness, fatigue, flatulence, etc will be recorded for 8 weeks.

Compare the Response Rate of Atypical GERD After PPI Therapy

evaluate the response rate (symptom free) during the 8-week PPI therapy for atypical GERD between dexlansoprazole group and lansoprazole group

dexilansoprazole (Dexilant 60 mg)

lansoprazole (Takepron OD 30 mg)

Taipei Veterans General Hospital

Comparison of the Efficiency of Two Different PPI Formula in Atypical GERD

Comparison of the Efficiency of Two Different PPI Formula in Treatment of Atypical GERD Patients, a Randomized Study

evaluate the response rate (symptom free) everyday during the 8-week PPI therapy for cough, globus sensation, NCCP, acid regurgitation, and heartburn respectively

the withdrawal or drop-out rate due to poor symptoms response or drug adverse effects

vghtpe user

Principal Investigator (and Clinical Professor)

Taipei Veterans General Hospital, Taiwan

a prospective, randomized, open-level clinical study to evaluate 8 weeks PPI response rate for atypical GERD

Active drug given to patients as an intravenous dose of 0.5 mg/kg of propofol

Placebo drug given to patients as an intravenous dose of 0.05 mL/kg of saline solution (NaCl 0.9%)

Elective Surgery

Coughing

Intravenous dose of 0.5 mg/kg of propofol

Intravenous dose of 0.05 mL/kg of saline solution

CHUM

Efficacy of Propofol vs Placebo in the Prevention of Coughing During Emergence of General Anesthesia Under Desflurane

Efficacy of an Intravenous Dose of Propofol Versus Placebo in the Prevention of Coughing During Emergence of General Anesthesia Under Desflurane

Incidence of coughing during emergence of general anesthesia (between discontinuation of desflurane and MAC of 0.15 of desflurane) and its severity based on a 4-grade scale

Incidence of coughing during emergence of general anesthesia (between MAC of 0.15 of desflurane and until 10 min after extubation) and its severity based on a 4-grade scale

Interval between discontinuation of desflurane and extubation

Sedation of the patient two, five and ten minutes following extubation, then at 15 minutes interval in the recovery room, based on the Observer's Assessment of Alertness/Sedation Scale (OAA/A), until 30 minutes after the admission in the recovery room

incidence of hypoventilation (breathing rate < 8/min)

incidence of hypoxic episode (oxygen saturation < 90%)

Measurement of blood pressure before the induction and during emergence (every 5 min) in order to calculate incidence of fluctuation of non invasive blood pressure and heart rate of more than 20% between the values before induction of anesthesia until 10 min after extubation

Measurement of heart rate before the induction and during emergence (every 5 min) in order to calculate incidence of fluctuation of non invasive blood pressure and heart rate of more than 20% between the values before induction of anesthesia until 10 min after extubation

Note the possible agitation of the patient during emergence

Describe potential complications secondary to the bolus of the substance under study at the emergence

Calculate cumulative incidence of nausea/vomiting between extubation and 30 minutes after the admission in the recovery room

Evaluate swallowing pain scores evaluated using a verbal simple numeric scale (0 = no pain et 10 = worst pain imaginable) 30 min after extubation

Centre hospitalier de l'Université de Montréal (CHUM)

Patients will then be randomized to receive placebo, consisting of 10ml of normal saline solution to be administered intravenously with the narcotic

Patients will be randomized to 6.25mg of promethazine, consisting of 0.25ml of promethazine diluted in 9.75ml of normal saline.

antitussives/illamående

Topical Bupivacaine Effect On The Response To Awake Extubation During Emergence From General Anesthesia

Comparison of the Efficiency of Two Different PPI Formula in Atypical GERD

Efficacy of Propofol vs Placebo in the Prevention of Coughing During Emergence of General Anesthesia Under Desflurane

Prevention of Narcotic-Induced Nausea

Methylphenidate Studies for Drug Abuse Vulnerability Molecular Genentics

Den mest kompletta databasen med medicinska örter som stöds av vetenskapen